Finasteride Side Effects: An Honest Account of a Contested Literature

This is one of the hardest questions in men’s health to answer honestly, because both confident positions are wrong. It is not true that finasteride is harmless and the complaints are imaginary. It is also not true that it routinely causes permanent sexual dysfunction. The evidence sits somewhere less satisfying than either camp wants.

What the trials found

A multicentre study reported drug-related sexual dysfunction in 8.7% of men on finasteride 1 mg against 5.1% on placebo. The excess attributable to the drug is therefore around 3.6 percentage points, roughly one man in 28.

Two features of that comparison are worth noticing.

First, the placebo rate is not zero. One man in twenty on a sugar pill reported sexual side effects. Sexual dysfunction is common in the general population of men, so a proportion of what gets attributed to any drug would have happened anyway.

Second, other trials found rates considerably lower. One 48-week study recorded two cases in the finasteride arm against one on placebo. The variation between trials is itself informative about how soft this outcome is to measure.

In the large trial programmes, sexual adverse effects were characterised as reversible and resolved after discontinuation.

The expectation problem

The most important study in this literature is not about finasteride’s pharmacology at all.

In 2007, researchers gave finasteride to 107 men. One group was counselled that the drug might cause sexual dysfunction. The other group was not told.

43.6% of the informed group reported sexual side effects. 14.3% of the uninformed group did. Same drug, same dose. A threefold difference produced entirely by what the men had been told to expect.

This is the nocebo effect, and it is a real physiological and psychological phenomenon rather than a way of calling people liars. Expectation genuinely shapes sexual function, anyone who has read about performance anxiety already knows this. A man watching anxiously for a problem is a man more likely to have one.

It also creates an unresolvable ethical bind. Informed consent requires telling men about possible side effects. Telling them appears to triple the rate at which they occur. There is no version of this where everybody wins.

The persistence question

Post-finasteride syndrome describes sexual dysfunction, and sometimes mood symptoms, persisting after the drug is stopped. Here the evidence genuinely conflicts.

Against: the Prostate Cancer Prevention Trial followed 17,313 men over seven years: the largest and longest dataset available, and none reported persistent sexual dysfunction.

For: case series exist. One reported that 89% of 54 participants still had sexual dysfunction at follow-up.

The gap between those two figures is enormous, and the methodological difference explains much of it. A case series recruits men who already believe they have been harmed. Selection bias and recall bias are near-total in that design, and there is no control group. That does not make the men wrong. It makes the study incapable of establishing whether they are right.

Reviewers of this literature have generally concluded that larger randomised controlled trials are needed to determine whether persistent effects are real or a red herring. That is an unsatisfying conclusion and it is the accurate one.

What I would not do is what both sides do: cite the case series as proof, or cite the trial as refutation. Neither settles it.

The effects that are not sexual

Two others are worth knowing about.

Mood. Depression and anxiety have been reported, and appear in the same contested literature with the same methodological problems. If your mood changes after starting, that is worth taking seriously and worth raising, not dismissing on the grounds that the evidence is unsettled. Depression in men presents in ways that get missed, which makes self-assessment unreliable.

PSA. Finasteride roughly halves prostate-specific antigen levels. This is not a side effect so much as a measurement artefact, and it matters enormously: if you have a PSA test while taking finasteride, whoever interprets it must know, or a meaningful result will be read as normal. If you are in the age band where the PSA conversation applies, tell them.

How to weigh this

The honest framing is a trade of a modest, mostly reversible risk against a cosmetic benefit that requires indefinite treatment. Reasonable men weigh that differently, and there is no correct answer that applies to everyone.

What makes it decidable for an individual is usually this: how much does the hair loss actually bother you? If the answer is “a great deal, and it affects how I move through the world,” a 3.6 percentage point excess risk of a usually reversible effect looks acceptable. If the answer is “I have not really thought about it, but my barber mentioned it,” it does not.

And bear in mind what you are signing up for. These drugs hold ground rather than banking it: stop, and the gains go. You are choosing a habit, not a course.

What to do

If you are considering it, know the real numbers rather than either the forum version or the prescriber’s version. Roughly one man in 28 above placebo, usually reversible.

If you start and something changes, do not quietly stop and tell nobody, which is what most men do. Tell whoever prescribed it. Stopping is a legitimate response, and it is the response with the best evidence behind it.

If a change persists after stopping, you are in genuinely uncertain territory, and you deserve a doctor who says so rather than one who tells you it is impossible. Working out whether an erection problem is physical or psychological is a useful place to start, because the answer changes what helps.

This article is for information only and is not medical advice. It cannot account for your individual circumstances. Talk to a doctor about your own situation, particularly before starting or stopping any prescription medication.